Literature DB >> 21745546

MDMA-induced c-Fos expression in oxytocin-containing neurons is blocked by pretreatment with the 5-HT-1A receptor antagonist WAY 100635.

Glenn E Hunt1, Iain S McGregor, Jennifer L Cornish, Paul D Callaghan.   

Abstract

The popular party drug MDMA (3,4-methylenedioxymethamphetamine, "Ecstasy") increases sociability in both humans and laboratory animals. Recent research suggests that these prosocial effects may involve serotonin (5-HT)-stimulated hypothalamic release of the neuropeptide oxytocin. WAY 100635, a 5-HT(1A) receptor antagonist, prevents MDMA-induced increases in plasma oxytocin and also reduces MDMA-mediated increases in social interaction in rats. The present study used c-Fos immunohistochemistry to determine the possible role of 5-HT(1A) receptors in MDMA-mediated activation of oxytocin synthesizing neurons. Male Wistar rats (n=8/group) were administered MDMA (10 mg/kg, i.p.) with or without WAY 100635 (1 mg/kg, i.p.) pre-treatment and c-Fos expression was then assessed throughout the brain. MDMA significantly increased locomotor activity and this effect was partly prevented by WAY 100635, in agreement with previous studies. WAY 100635 significantly reduced MDMA-induced c-Fos expression in a subset of brain regions examined. A particularly prominent reduction was seen in the oxytocin-positive neurons of the supraoptic nucleus and paraventricular hypothalamus, with more modest reductions in the Islands of Calleja, median preoptic nucleus, somatosensory cortex and nucleus of the solitary tract. WAY 100635 did not alter MDMA-induced c-Fos expression in the striatum, thalamus, or central amygdala. These results indicate that MDMA's action on oxytocin producing cells in the hypothalamus is mediated through 5-HT(1A) receptors and that certain specific cortical, limbic and brainstem sites are also activated by MDMA via these receptors.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21745546     DOI: 10.1016/j.brainresbull.2011.06.011

Source DB:  PubMed          Journal:  Brain Res Bull        ISSN: 0361-9230            Impact factor:   4.077


  20 in total

Review 1.  The prosocial effects of 3,4-methylenedioxymethamphetamine (MDMA): Controlled studies in humans and laboratory animals.

Authors:  Philip Kamilar-Britt; Gillinder Bedi
Journal:  Neurosci Biobehav Rev       Date:  2015-09-25       Impact factor: 8.989

2.  3,4-Methylenedioxymethamphetamine Increases Affiliative Behaviors in Squirrel Monkeys in a Serotonin 2A Receptor-Dependent Manner.

Authors:  Elizabeth G Pitts; Adelaide R Minerva; Erika B Chandler; Jordan N Kohn; Meghan T Logun; Agnieszka Sulima; Kenner C Rice; Leonard L Howell
Journal:  Neuropsychopharmacology       Date:  2017-04-20       Impact factor: 7.853

3.  (S)-5-(2'-Fluorophenyl)-N,N-dimethyl-1,2,3,4-tetrahydronaphthalen-2-amine, a Serotonin Receptor Modulator, Possesses Anticonvulsant, Prosocial, and Anxiolytic-like Properties in an Fmr1 Knockout Mouse Model of Fragile X Syndrome and Autism Spectrum Disorder.

Authors:  Jessica L Armstrong; Austen B Casey; Tanishka S Saraf; Munmun Mukherjee; Raymond G Booth; Clinton E Canal
Journal:  ACS Pharmacol Transl Sci       Date:  2020-02-21

4.  Comparison of in vivo binding properties of the 18-kDa translocator protein (TSPO) ligands [(18)F]PBR102 and [ (18)F]PBR111 in a model of excitotoxin-induced neuroinflammation.

Authors:  P D Callaghan; C A Wimberley; G L Rahardjo; P J Berghofer; T Q Pham; T Jackson; D Zahra; T Bourdier; N Wyatt; I Greguric; N R Howell; R Siegele; Z Pastuovic; F Mattner; C Loc'h; M C Gregoire; A Katsifis
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-09-18       Impact factor: 9.236

Review 5.  Perspectives on zebrafish models of hallucinogenic drugs and related psychotropic compounds.

Authors:  Nikhil Neelkantan; Alina Mikhaylova; Adam Michael Stewart; Raymond Arnold; Visar Gjeloshi; Divya Kondaveeti; Manoj K Poudel; Allan V Kalueff
Journal:  ACS Chem Neurosci       Date:  2013-08-06       Impact factor: 4.418

6.  Inhibition of serotonin transporters disrupts the enhancement of fear memory extinction by 3,4-methylenedioxymethamphetamine (MDMA).

Authors:  Matthew B Young; Seth D Norrholm; Lara M Khoury; Tanja Jovanovic; Sheila A M Rauch; Collin M Reiff; Boadie W Dunlop; Barbara O Rothbaum; Leonard L Howell
Journal:  Psychopharmacology (Berl)       Date:  2017-07-24       Impact factor: 4.530

7.  Oxytocin and MDMA ('Ecstasy') enhance social reward in rats.

Authors:  Linnet Ramos; Callum Hicks; Alex Caminer; Jack Goodwin; Iain S McGregor
Journal:  Psychopharmacology (Berl)       Date:  2015-03-15       Impact factor: 4.530

Review 8.  The serotonin system in autism spectrum disorder: From biomarker to animal models.

Authors:  C L Muller; A M J Anacker; J Veenstra-VanderWeele
Journal:  Neuroscience       Date:  2015-11-11       Impact factor: 3.590

9.  Acute prosocial effects of oxytocin and vasopressin when given alone or in combination with 3,4-methylenedioxymethamphetamine in rats: involvement of the V1A receptor.

Authors:  Linnet Ramos; Callum Hicks; Richard Kevin; Alex Caminer; Rajeshwar Narlawar; Michael Kassiou; Iain S McGregor
Journal:  Neuropsychopharmacology       Date:  2013-05-16       Impact factor: 7.853

10.  The nonpeptide oxytocin receptor agonist WAY 267,464: receptor-binding profile, prosocial effects and distribution of c-Fos expression in adolescent rats.

Authors:  C Hicks; W Jorgensen; C Brown; J Fardell; J Koehbach; C W Gruber; M Kassiou; G E Hunt; I S McGregor
Journal:  J Neuroendocrinol       Date:  2012-07       Impact factor: 3.627

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.